Browse > Article
http://dx.doi.org/10.5808/GI.2015.13.4.132

Expressional Subpopulation of Cancers Determined by G64, a Co-regulated Module  

Min, Jae-Woong (Department of Medical Biotechnology, College of Biomedical Science, and Institute of Bioscience & Biotechnology)
Choi, Sun Shim (Department of Medical Biotechnology, College of Biomedical Science, and Institute of Bioscience & Biotechnology)
Abstract
Studies of cancer heterogeneity have received considerable attention recently, because the presence or absence of resistant sub-clones may determine whether or not certain therapeutic treatments are effective. Previously, we have reported G64, a co-regulated gene module composed of 64 different genes, can differentiate tumor intra- or inter-subpopulations in lung adenocarcinomas (LADCs). Here, we investigated whether the G64 module genes were also expressed distinctively in different subpopulations of other cancers. RNA sequencing-based transcriptome data derived from 22 cancers, except LADC, were downloaded from The Cancer Genome Atlas (TCGA). Interestingly, the 22 cancers also expressed the G64 genes in a correlated manner, as observed previously in an LADC study. Considering that gene expression levels were continuous among different tumor samples, tumor subpopulations were investigated using extreme expressional ranges of G64-i.e., tumor subpopulation with the lowest 15% of G64 expression, tumor subpopulation with the highest 15% of G64 expression, and tumor subpopulation with intermediate expression. In each of the 22 cancers, we examined whether patient survival was different among the three different subgroups and found that G64 could differentiate tumor subpopulations in six other cancers, including sarcoma, kidney, brain, liver, and esophageal cancers.
Keywords
differentially expressed genes; lung adenocarcinoma; single cell analysis; survival analyses; tumor heterogeneity;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Hayama S, Daigo Y, Yamabuki T, Hirata D, Kato T, Miyamoto M, et al. Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis. Cancer Res 2007;67:4113-4122.   DOI
2 Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 2000;60:4000-4004.
3 Zhong X, Guan X, Dong Q, Yang S, Liu W, Zhang L. Examining Nek2 as a better proliferation marker in non-small cell lung cancer prognosis. Tumour Biol 2014;35:7155-7162.   DOI
4 Beer D, Taylor J, Chen G, Kim S. Lung cancer signature. United States patent US 20120295803 A1. 2012 Nov 22.
5 Nguyen MH, Koinuma J, Ueda K, Ito T, Tsuchiya E, Nakamura Y, et al. Phosphorylation and activation of cell division cycle associated 5 by mitogen-activated protein kinase play a crucial role in human lung carcinogenesis. Cancer Res 2010;70: 5337-5347.   DOI
6 Goodwin G, Johns E, Lehn D, Landsman D, Wright J, Ferrari S, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Biol Chem 1986;261: 2274.
7 Pan H, Griep AE. Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. Genes Dev 1994;8:1285-1299.   DOI
8 Sherr CJ. Cancer cell cycles. Science 1996;274:1672-1677.   DOI
9 Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 2002;13:1977-2000.   DOI
10 Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature 2013;501:355-364.   DOI
11 Cusnir M, Cavalcante L. Inter-tumor heterogeneity. Hum Vaccin Immunother 2012;8:1143-1145.   DOI
12 Lyng H, Vorren AO, Sundfor K, Taksdal I, Lien HH, Kaalhus O, et al. Intra- and intertumor heterogeneity in blood perfusion of human cervical cancer before treatment and after radiotherapy. Int J Cancer 2001;96:182-190.   DOI
13 Jiang YH, Yuen RK, Jin X, Wang M, Chen N, Wu X, et al. Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing. Am J Hum Genet 2013;93:249-263.   DOI
14 Pinto N, Dolan ME. Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab 2011;12:487-497.   DOI
15 Timmermann B, Kerick M, Roehr C, Fischer A, Isau M, Boerno ST, et al. Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS One 2010;5:e15661.   DOI
16 Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008;84:417-423.   DOI
17 Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013;502:333-339.   DOI
18 Roukos D, Batsis C, Baltogiannis G. Assessing tumor heterogeneity and emergence mutations using next-generation sequencing for overcoming cancer drugs resistance. Expert Rev Anticancer Ther 2012;12:1245-1248.   DOI
19 Min JW, Kim WJ, Han JA, Jung YJ, Kim KT, Park WY, et al. Identification of Distinct Tumor Subpopulations in Lung Adenocarcinoma via Single-Cell RNA-seq. PLoS One 2015;10:e0135817.   DOI
20 Miyagi A, Takahashi H, Takahara K, Hirabayashi T, Nishimura Y, Tezuka T, et al. Principal component and hierarchical clustering analysis of metabolites in destructive weeds; polygonaceous plants. Metabolomics 2010;6:146-155.   DOI
21 Cox DR. Regression models and life-tables. J R Stat Soc Series B Methodol 1972;34:187-220.
22 Efron B. Logistic regression, survival analysis, and the Kaplan-Meier curve. J Am Stat Assoc 1988;83:414-425.   DOI